<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737746</url>
  </required_header>
  <id_info>
    <org_study_id>B1172020000048</org_study_id>
    <secondary_id>CME AZ Delta</secondary_id>
    <nct_id>NCT04737746</nct_id>
  </id_info>
  <brief_title>Caregiver Burden and Correlation With Clinical Outcome in Spinal Cord Stimulation for Chronic Neuropathic Pain</brief_title>
  <acronym>CAREstim</acronym>
  <official_title>Caregiver Burden and Correlation With Clinical Outcome in Spinal Cord</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Delta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Delta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicentric observational trial on caregiver burden, caregiver satisfaction and&#xD;
      clinical outcome in spinal cord stimulation for chronic neuropathic pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal cord stimulation is an effective therapy for chronic neuropathic pain. After careful&#xD;
      selection, the satisfaction for the patient is often considerable. The investigators want to&#xD;
      investigate the caregiver burden for relatives of patients who are treated with spinal cord&#xD;
      stimulation. This will be evaluated by appropriate scores at baseline, during neurostimulator&#xD;
      trial and 3,6 and 12 months after implantation. At the same time the patient satisfaction and&#xD;
      pain reduction will also be evaluated independently.&#xD;
&#xD;
      In this prospective cohort different parameters will be assessed at baseline, trial, 3, 6 and&#xD;
      12 months follow-up for the patient and their caregiver.&#xD;
&#xD;
      For the patient this will include Numeric Rating scale (NRS) for leg and back pain, Oswestry&#xD;
      Disability Index (ODI), EuroQuality of Life-5 Dimensions score (EQ5D), opiate use and&#xD;
      Relation Quality Index (RQI).&#xD;
&#xD;
      For the caregiver the Zarit Burden Index (ZBI), Relation Quality Index (RQI) and Modified&#xD;
      Caregiver Strain Index (MCSI).&#xD;
&#xD;
      With regard to the research questions, subgroup analysis will be performed regarding to age,&#xD;
      sex, education, neurostimulation pattern, surgical vs percutaneous lead placement, working&#xD;
      status of both patient and caregiver and caregiver relation characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>13 Months</target_duration>
  <primary_outcome>
    <measure>Zarit Burden index</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>Zarit Burden index measures the burden of a caregiver in 12 questions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>relation quality index caregiver</measure>
    <time_frame>baseline to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>caregiver strain index</measure>
    <time_frame>baseline to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS pain leg and back</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>numeric rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimensions EQ-5D</measure>
    <time_frame>baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relation quality index patient</measure>
    <time_frame>baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analgetics dose</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>analgetics ( paracetamol, opiates, opioids, non steroidal anti inflammatory and anti neuropathic pain medication</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pain, Chronic</condition>
  <condition>Pain, Neuropathic</condition>
  <condition>Failed Back Surgery Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who are considered to be treated with spinal cord stimulation in AZ Delta&#xD;
        hospital and Jan Yperman hospital between 1/1/2021 and 31/12/2021 are potentially eligible&#xD;
        for inclusion. The inclusion is not limited to a specific device and all different types of&#xD;
        routinely used spinal cord stimulation systems and neurostimulation modalities are&#xD;
        included: percutaneous of surgical lead placement in both thoracic or cervical location.&#xD;
        All patients follow the standard flow for screening and reimbursement (neuro pain platform&#xD;
        and MAO)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients Age &gt; 18 years&#xD;
&#xD;
          -  Patients with an identified spousal or offspring caregiver&#xD;
&#xD;
          -  Patients receiving neurostimulator for the first time&#xD;
&#xD;
          -  Patient complies to reimbursement criteria for spinal cord stimulation in Belgium&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-spinal cord type of neuromodulation (DRG, occipital, peripheral nerve, )&#xD;
&#xD;
          -  Revision cases, previous neuromodulation&#xD;
&#xD;
          -  Patients unable to consent for this study&#xD;
&#xD;
          -  Patients without identified spousal or offspring caregiver&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dimitri J Vanhauwaert, MD</last_name>
    <phone>+3251237440</phone>
    <email>dimitri.vanhauwaert@azdelta.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stijn Van Damme</last_name>
    <phone>+3251237440</phone>
    <email>stijn.vandamme@azdelta.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jan Ypermanziekenhuis</name>
      <address>
        <city>Ieper</city>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick De Nayer, MD</last_name>
      <phone>+3251353535</phone>
    </contact>
    <contact_backup>
      <last_name>Julie Depauw</last_name>
      <phone>+3257353535</phone>
      <email>julie.depauw@yperman.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Vanhauwaert, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Delta</investigator_affiliation>
    <investigator_full_name>Dimitri Vanhauwaert</investigator_full_name>
    <investigator_title>neurosurgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Failed Back Surgery Syndrome</mesh_term>
    <mesh_term>Caregiver Burden</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

